USD10
CELC Shares
About CelcuityCelcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
USD10
CELC Shares
About CelcuityCelcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 20 at 1:30 PM GMT+0
MARKET CAP
$5.24B
OPEN PRICE
Not enough data
LOW (1Y)
$7.58
HIGH (1Y)
$120.32
LOW (24H)
$107.12
HIGH (24H)
$116.37
VOLUME (24H)
$2.52K
99.56%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $111.14 | |
1 Week | $114.55 | |
1 Month | $105.21 | |
1 Year | $10.50 |